<DOC>
	<DOCNO>NCT02708641</DOCNO>
	<brief_summary>This phase II study evaluate effect pembrolizumab duration remission acute myeloid leukemia . Pembrolizumab give complete remission obtain AML least 60 year old candidate allogeneic stem cell transplant . The primary purpose study determine time relapse extend . Additionally , safety tolerability pembrolizumab closely monitor .</brief_summary>
	<brief_title>A Phase II Study Pembrolizumab Post-Remission Treatment Patients ≥ 60 With AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>willing able provide write informed consent trial ≥ 60 year age day sign informed consent newly diagnose AML base World Health Organization ( WHO ) criterion , currently first complete remission ( CR ) bone marrow biopsy perform within 4 week treatment initiation receive last dose induction consolidation chemotherapy within 3 month treatment initiation eligible willing proceed allogeneic stem cell transplant allogeneic stem cell transplant consider standard care performance status ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale demonstrate adequate organ function , screen lab perform within 10 day treatment initiation transfusion independent ( red blood cell platelet transfusion precede 2 week screen ) negative urine and/or serum pregnancy test subject reproductive potential must agree use acceptable birth control method diagnosis Acute Promyelocytic Leukemia ( APL ) define WHO currently participate participate study investigational agent device within 4 week treatment initiation diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior treatment initiation prior monoclonal antibody within 4 week prior study Day 1 recover adverse event due agent administer 4 week earlier prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover adverse event due previously administer agent ( ) know additional malignancy progress require active treatment except basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy know active central nervous system ( CNS ) involvement active autoimmune disease require systemic treatment within past 3 month evidence interstitial lung disease active , noninfectious pneumonitis uncontrolled , lifethreatening active infection history current evidence condition , therapy , laboratory abnormality would preclude study participation opinion treat investigator know psychiatric substance abuse disorder would interfere cooperation trial requirement pregnant breastfeeding , expect conceive father child within project duration trial receive prior therapy antibody target Tcell costimulation checkpoint pathway know history HIV know active Hepatitis B Hepatitis C receive live vaccine within 30 day prior treatment initiation</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>